The stock of Quest Diagnostics Incorporated (NYSE:DGX) increased by increased by $1.13 on Friday to finish at $146.49, up 0.78 percent. The last five days have seen an average of 1,571,040 shares of common stock traded. 26 times new highs were reached in the current year, with a gain of $27.32. The average number of shares traded over the last 20 days was 1,481,605, while the average volume over the last 50 days totaled 1,300,758.
DGX stock dropped -4.58% since last month. On 10/13/21, the company’s shares reached a one-month low of $139.61. The stock touched a high of $160.56 on 09/09/21, after rallying from a low of $113.36 in 52 weeks. The price of DGX stock has risen by 22.93% or $27.32 this year, reaching a new high 26 times. Still, the stock price is down -8.76% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
There have been 88 days since Quest Diagnostics Incorporated (DGX) last reported insider trading activity on Jul 29. On Jul 29, Chairman, CEO and President RUSCKOWSKI STEPHEN H sold 9,493 shares at $140.87 each. This transaction resulted in the insider making $1,337,251. On Jul 28, RUSCKOWSKI STEPHEN H sold 139,751 shares at a price of US$140.14. After the transaction, the insider now owns 284,427 shares. Director WILENSKY GAIL R had earlier sold 12,222 shares on Jul 27 for $139.30 a share. The transaction was completed for $1,702,470.
Quest Diagnostics Incorporated (DGX) has a trailing price-to-earnings (P/E) ratio of 8.79. This level actually compares favorably with the industry at large, as the PE for the Diagnostics & Research industry stands at about 37.02. Further, its PE also compares favorably with the Healthcare sector’s trailing 12 months PE ratio, which comes in at 33.43 right now. The PE ratio of Quest Diagnostics Incorporated has varied between 23.60 and 7.869 in the last five years. Beta for the stock is 1.01. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 1.61, the price-to-book (PB) ratio of 3.10, and the price-to-cash flow ratio of 10.05.
Quest Diagnostics Incorporated’s dividend is $2.48 per share per year. With a dividend yield of 1.69%, DGX has a payout ratio of 16.70%. On Oct. 20, the company paid $0.62 per share in dividends, remained unchanged from $0.62 last year. A $0.06 dividend increase was reported on Thursday February 4 2021, making it the 10 consecutive year the dividend has increased. Over the last three years, dividends have increased by 22.78%.
For the three months ended June 29, Quest Diagnostics Incorporated’s quick ratio was 1.30, while its current ratio was 1.40, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.68, and the total debt to equity ratio is 0.68. As far as profitability goes, gross margin for the trailing twelve months is 40.80% percent. Quest Diagnostics Incorporated’s EBITDA margin for the year ended June 29 was 26.13%, whereas its operating margin stood at 22.20% for the same period. Based on annual data, it had gross profit of $3.63 billion and revenue of $9.44 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. DGX’s return on assets (ROA) during the last 12 months has been 13.10%. There was a 13.80% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 27.80%. ROE has averaged -2.89 in the past year for the broader industry.
According to Quest Diagnostics Incorporated’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $2.77 billion, while revenues fell by -0.43% to $2.55 billion. It was predicted that Quest Diagnostics Incorporated’s quarterly earnings would be $3.18, but it ended up being $2.87, beating the consensus by 10.80%. EBITDA was $633.0 million for the quarter. At the end of Quest Diagnostics Incorporated’s most recent quarter ended June 29, its liabilities totaled 6.92 billion, while its total debt was $4.65 billion. Equity owned by shareholders amounts to $122.18 million.
Here’s a quick look at Quest Diagnostics Incorporated’s (DGX) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 57.70%, suggesting the stock is Neutral, with a 9.87% historical volatility rate.
The stochastic %K and %D were 73.63% and 70.50% respectively, while the average true range (ATR) was 3.06. Based on the 14-day stochastic reading of 72.12%, the RSI (14) reading is 52.02%. On the 9-day MACD Oscillator, the stock is at 2.40, and the 14-day reading is at 3.11.
In its most recent analyst report, UBS raised its rating on Quest Diagnostics Incorporated (NYSE: DGX) to a Buy. Prior to this, analysts firm rated the stock as a Neutral. Analysts have assigned Quest Diagnostics Incorporated (DGX) an Overweight rating. DGX is a stock that is recommended for selling by 0 brokerage firms, while 7 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 10 others recommend it as a buy.